Drugs / CBP-0276
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07708831 | Sep 2025 → Feb 2026 | — | Clarent Biopharma, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07706530 | Jul 2026 → Feb 2027 expected | psoriatic arthritis | Clarent Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07687966 | May → Jun 2026 overdue | — | Clarent Biopharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07204639 | Oct 2025 → Jul 2026 overdue | psoriasis | Clarent Biopharma, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-0276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07706530 ↗ |
| Route | Oral | “CBP-0276 200mg twice a day, orally for 30 weeks” NCT07204639 ↗ |